Xencor (XNCR) | Financial Analysis & Statements
Xencor Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
28.2M
Operating Income
-53.6M
-189.92%
Net Income
-6.7M
-23.56%
Balance Sheet Metrics
Total Assets
875.5M
Total Liabilities
239.9M
Shareholders Equity
635.6M
Debt to Equity
0.38
Cash Flow Metrics
Operating Cash Flow
-8.5M
Free Cash Flow
-52.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Xencor Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 125.6M | 110.5M | 168.3M | 164.6M | 275.1M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 239.4M | 227.7M | 253.6M | 199.6M | 192.5M |
| Selling, General & Administrative | 63.6M | 61.2M | 53.4M | 47.5M | 38.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 303.1M | 288.9M | 307.0M | 247.1M | 231.3M |
| Operating Income | -177.5M | -178.4M | -138.6M | -82.5M | 43.8M |
| Operating Margin % | -141.4% | -161.5% | -82.4% | -50.1% | 15.9% |
| Non-Operating Items | |||||
| Interest Income | 27.5M | 31.9M | 18.6M | 4.8M | 849.0K |
| Interest Expense | 31.9M | 36.6M | - | - | - |
| Other Non-Operating Income | 92.3M | -51.8M | -426.0K | 23.1M | 38.0M |
| Pre-tax Income | -89.6M | -234.9M | -120.4M | -54.5M | 82.6M |
| Income Tax | 2.5M | 1.6M | 5.8M | 673.0K | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -92.1M | -236.5M | -126.2M | -55.2M | 82.6M |
| Net Margin % | -73.4% | -214.1% | -75.0% | -33.5% | 30.0% |
| Key Metrics | |||||
| EBITDA | -139.5M | -134.3M | -126.7M | -97.1M | 12.0M |
| EPS (Basic) | $-1.24 | $-3.58 | $-2.08 | $-0.93 | $1.42 |
| EPS (Diluted) | $-1.24 | $-3.58 | $-2.08 | $-0.93 | $1.37 |
| Basic Shares Outstanding | 74239000 | 65041265 | 60503283 | 59652461 | 58379641 |
| Diluted Shares Outstanding | 74239000 | 65041265 | 60503283 | 59652461 | 58379641 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Xencor Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 54.1M | 40.9M | 53.8M | 53.9M | 143.5M |
| Short-term Investments | 493.7M | 456.9M | 539.9M | 569.1M | 190.6M |
| Accounts Receivable | 29.3M | 60.8M | 11.3M | 29.0M | 66.4M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 22.8M | 19.0M | 18.1M | 23.3M | 23.9M |
| Total Current Assets | 599.8M | 577.6M | 623.2M | 675.3M | 424.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 81.3M | 38.3M | 34.0M | 34.4M | 31.7M |
| Goodwill | 8.4M | 18.5M | 18.7M | 18.5M | 16.5M |
| Intangible Assets | 8.4M | 18.5M | 18.7M | 18.5M | 16.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 787.0K | 885.0K | 1.0M | 613.0K | 653.0K |
| Total Non-Current Assets | 275.7M | 374.3M | 329.5M | 170.9M | 413.8M |
| Total Assets | 875.5M | 951.9M | 952.7M | 846.3M | 838.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 10.8M | 16.8M | 13.9M | 10.1M | 14.0M |
| Short-term Debt | 46.5M | 51.5M | 9.8M | 4.7M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 95.9M | 87.4M | 84.7M | 63.8M | 70.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 141.2M | 180.5M | 73.7M | 54.9M | 34.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 144.0M | 190.5M | 198.8M | 54.9M | 34.0M |
| Total Liabilities | 239.9M | 277.9M | 283.6M | 118.8M | 104.7M |
| Equity | |||||
| Common Stock | 718.0K | 703.0K | 611.0K | 601.0K | 595.0K |
| Retained Earnings | -796.0M | -704.0M | -464.4M | -338.3M | -283.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 635.6M | 674.0M | 669.1M | 727.5M | 733.5M |
| Key Metrics | |||||
| Total Debt | 187.7M | 232.0M | 83.4M | 59.6M | 34.0M |
| Working Capital | 503.9M | 490.2M | 538.5M | 611.5M | 353.6M |
Balance Sheet Composition
Xencor Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -92.1M | -236.5M | -126.2M | -55.2M | 82.6M |
| Depreciation & Amortization | 10.5M | 12.1M | 11.5M | 8.8M | 7.5M |
| Stock-Based Compensation | 43.2M | 53.3M | 53.8M | 48.9M | 37.0M |
| Working Capital Changes | 24.2M | -36.2M | 156.1M | 48.9M | -90.8M |
| Operating Cash Flow | -62.5M | -237.7M | 85.8M | 46.1M | 13.9M |
| Investing Activities | |||||
| Capital Expenditures | -3.2M | -6.1M | -18.4M | -38.5M | -13.3M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -298.9M | -595.1M | -782.9M | -387.9M | -509.6M |
| Investment Sales | 442.0M | 596.7M | 693.1M | 306.6M | 485.2M |
| Investing Cash Flow | 140.0M | -4.5M | -108.3M | -114.8M | -43.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -1.7M | 189.2M | 20.8M | 0 | 28.9M |
| Free Cash Flow | -138.3M | -211.7M | 63.9M | -18.9M | -32.8M |
| Net Change in Cash | 75.7M | -53.0M | -1.7M | -68.7M | -778.0K |
Cash Flow Trend
Xencor Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-10.48
Forward P/E
-4.27
Price to Book
1.47
Price to Sales
7.58
PEG Ratio
0.12
Profitability Ratios
Profit Margin
-73.20%
Operating Margin
-189.92%
Return on Equity
-14.07%
Return on Assets
-12.14%
Financial Health
Current Ratio
6.25
Debt to Equity
29.54
Beta
0.99
Per Share Data
EPS (TTM)
$-1.24
Book Value per Share
$8.84
Revenue per Share
$1.69
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| XNCR | 951.9M | -10.48 | 1.47 | -14.07% | -73.20% | 29.54 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Amylyx | 1.9B | 2.54 | 6.31 | -61.59% | 0.00% | 1.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.






